Company Overview - Tango Therapeutics, Inc. (TNGX) shares increased by 7.5% to close at $5.16, with notable trading volume compared to typical sessions, and a total gain of 157.4% over the past four weeks [1][2] Pipeline Developments - The company recently dosed the first patient in the TNG456 phase I/II study targeting MTAP-deleted solid tumors, particularly glioblastoma, which has contributed to positive market sentiment regarding its pipeline of precision cancer medicines [2] Financial Expectations - Tango Therapeutics is projected to report a quarterly loss of $0.36 per share, reflecting a year-over-year decline of 50%, with expected revenues of $5.79 million, down 70.9% from the previous year [3] - The consensus EPS estimate for the quarter has been revised slightly higher in the last 30 days, indicating a potential for price appreciation if the trend continues [4] Industry Context - Tango Therapeutics operates within the Zacks Medical - Biomedical and Genetics industry, where it holds a Zacks Rank of 3 (Hold) [5] - Another company in the same industry, Protagonist Therapeutics (PTGX), experienced a 1.1% decline in its stock price, with a monthly return of 17.5% [5][6]

Summary of Tango Therapeutics Conference Call Company Overview - **Company**: Tango Therapeutics - **Industry**: Biotechnology, specifically focused on oncology and synthetic lethality Core Insights and Arguments - **Synthetic Lethality Platform**: Tango's discovery platform is based on synthetic lethality, which targets tumor suppressor gene loss that cannot be directly targeted due to their inactivation. This approach supplements existing therapies that focus on activated oncogenes [2][3] - **Pipeline Development**: Tango is advancing its lead asset, TNG-462, a PRMT5 inhibitor, which is synthetic lethal with MTAP deletions, common in lung and pancreatic cancers. The company is nearing the end of a Phase III study for this asset [8][9] - **Durability of Treatment**: The efficacy of TNG-462 is highlighted by its durability in patients, with some remaining on treatment for over a year, which is notable compared to standard chemotherapy options [10][11] - **Tolerability Profile**: TNG-462 is reported to have a best-in-class tolerability profile, making it suitable for patients with difficult-to-treat cancers [12] Pipeline Details - **TNG-462**: Focused on pancreatic and lung cancers, with plans to present data from over 20 patients in each category later this year [10] - **TNG-456**: A next-generation brain-penetrant asset aimed at glioblastoma, which has a high prevalence of MTAP deletions. This asset is expected to deliver more drug into the brain due to increased selectivity [13][15] - **TNG-260**: A coREST inhibitor targeting STK11 mutation patients, which represents a significant opportunity in non-small cell lung cancer. The program is currently in dose expansion [30][31] Competitive Landscape - **Key Competitors**: The primary competitors identified are Bristol Myers Squibb (BMS) and Amgen, with Tango believing it has a competitive edge in terms of pharmacokinetics (PK) and tolerability [21][22] - **Market Positioning**: Tango positions itself as a leader in the PRMT5 space, with a significant lead over other companies like AstraZeneca and BeiGene [22] Combination Strategies - **Combination with RAS Mutations**: Tango is initiating a study combining TNG-462 with RAS mutation-targeted therapies, which is expected to be transformative for pancreatic and lung cancer patients [27] - **Focus on Tolerability**: The company is monitoring overlapping toxicities in combination therapies but expects good tolerability based on existing safety profiles [29] Financial and Strategic Focus - **Capital Allocation**: Tango's capital allocation strategy is heavily focused on advancing the development of TNG-462 for pancreatic cancer, with plans to start a pivotal study next year [38] - **Investor Perception**: There is a belief that investors have underestimated the importance of PRMT5 as a target and Tango's position in the market. The company asserts it is well-resourced to compete effectively [36][37] Additional Insights - **Innovative Approach**: Tango's approach to synthetic lethality and its focus on specific genetic mutations (like STK11 and MTAP) are seen as innovative and potentially game-changing in oncology [30][31] - **Clinical Proof of Concept**: The company has demonstrated that its findings in animal models translate to human patients, reinforcing the validity of its therapeutic strategies [32][34]

IR@tangotx.com Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more information, please visit www.tangotx.com. Investors and Media: Elizabeth Hickin BOSTON, May 27, 2025 ( ...

Forward-Looking Statements Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events, Tango's future operating performance and goals, the anticipated benefits of therapies and combination therapies (that include a Tango pipeline product), as well as the expectations, beliefs and development objectives for Tango's product pipeline and clinical trials. In some cases, you can identify forward-looking statements by termino ...

Company Performance - Tango Therapeutics reported a quarterly loss of $0.36 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.34, and compared to a loss of $0.35 per share a year ago, indicating an earnings surprise of -5.88% [1] - The company posted revenues of $5.39 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 13.94%, and down from $6.47 million in the same quarter last year [2] - Over the last four quarters, Tango Therapeutics has surpassed consensus EPS estimates two times and topped consensus revenue estimates two times [2] Stock Performance - Tango Therapeutics shares have declined approximately 63.1% since the beginning of the year, contrasting with the S&P 500's decline of -3.8% [3] - The current consensus EPS estimate for the upcoming quarter is -$0.34 on revenues of $5.72 million, and for the current fiscal year, it is -$1.37 on revenues of $28.53 million [7] Industry Outlook - The Medical - Biomedical and Genetics industry, to which Tango Therapeutics belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to the bottom 50% of ranked industries [8] - The performance of Tango Therapeutics may be influenced by the overall industry outlook, as empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions [5][8]

Financial Overview - Tango Therapeutics has raised an aggregate of $166.9 million from preferred shares, $342.1 million from a Business Combination, $237.1 million from collaboration with Gilead, and $123.0 million from common shares and stock offerings [103][104]. - As of March 31, 2025, the company has $216.7 million in cash and equivalents, expected to fund operations into Q1 2027 [105]. - For the three months ended March 31, 2025, the net loss was $39.9 million, compared to $37.9 million for the same period in 2024, with an accumulated deficit of $541.4 million [105]. - The company has not generated any revenue from product sales and does not expect to do so in the next several years [106][109]. - Collaboration revenue recognized from Gilead agreements totaled $142.0 million as of March 31, 2025, with $5.4 million recognized in Q1 2025 [112]. - Collaboration revenue decreased to $5.4 million for the three months ended March 31, 2025, down from $6.5 million in the same period of 2024, a decline of approximately 17% [130]. - Interest income decreased to $1.6 million for the three months ended March 31, 2025, down from $2.2 million in 2024, a decline of about 27% attributed to a decrease in marketable securities [133]. - Net cash used in operating activities was $41.7 million for the three months ended March 31, 2025, compared to $37.9 million in 2024, an increase of $3.8 million [139]. - Net cash provided by investing activities was $30.6 million for the three months ended March 31, 2025, compared to net cash used of $11.2 million in 2024, a change of $41.8 million [140]. - As of March 31, 2025, the company had cash and cash equivalents and marketable securities totaling $216.7 million, expected to fund operations into the first quarter of 2027 [137]. - The company recorded a net loss of $39.9 million for the three months ended March 31, 2025, compared to a net loss of $37.9 million in 2024, an increase of $1.9 million [129]. - Total operating expenses were $47.9 million for the three months ended March 31, 2025, down from $48.7 million in 2024, a decrease of $0.8 million [129]. Research and Development - Research and development expenses for Q1 2025 totaled $36.4 million, a decrease from $38.1 million in Q1 2024 [118]. - The company plans to increase research and development expenses significantly as it advances its product candidates and clinical trials [120]. - Research and development expenses were $36.4 million for the three months ended March 31, 2025, compared to $38.1 million in 2024, reflecting a decrease of $1.6 million primarily due to the discontinuation of certain clinical programs [131]. - TNG462 is currently in a Phase 1/2 trial, with plans for a clinical data update in the second half of 2025 [98]. - TNG456 has received FDA clearance for IND and is set to begin a Phase 1/2 trial in Q2 2025 [100]. - TNG260 is in the dose expansion phase of its trial, with clinical data expected in the second half of 2025 [101]. General and Administrative Expenses - General and administrative expenses increased to $11.5 million for the three months ended March 31, 2025, up from $10.7 million in 2024, an increase of approximately 7.5% [132]. - The company anticipates an increase in general and administrative expenses in the future due to headcount growth and associated costs [124]. Revenue Recognition and Accounting - Revenue from license payments is recognized upon delivery and customer ability to use the license, with significant judgment involved in determining distinct performance obligations [150]. - Milestone payments are included in transaction price only if they are probable to not face significant reversal, with regulatory approval milestones considered constrained until approval is received [151]. - ASC 606 requires allocation of arrangement consideration based on relative standalone selling price for each performance obligation, with key assumptions including forecasted revenues and development timelines [152]. - Revenue is recognized over time for combined performance obligations that include services, using the cost-to-cost input method [153]. - Deferred revenue is recorded as a contract liability for amounts not meeting revenue recognition criteria, with short-term deferred revenue expected to be recognized within the next 12 months [154]. - Estimates of accrued research and development expenses are made based on service levels and costs incurred, with adjustments made as necessary [157]. - The company records expenses related to research and development based on estimates of services received, with potential for uneven payment flows [158]. - Recently adopted accounting pronouncements that may impact financial position are disclosed in the quarterly and annual reports [159]. - There were no material changes to market risks as described in the previous annual report [160].

Tango Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Highlights – Data update from ongoing TNG462 Phase 1/2 monotherapy trial expected 2H 2025 – – Combination trial of TNG462 + Revolution Medicines RAS(ON) inhibitors on track for enrollment 2Q 2025 – – Cash position of $217 million as of March 31, 2025; cash runway extended into 1Q 2027 - with reduction of preclinical spend – BOSTON, May 12, 2025 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage b ...

Company Overview - Tango Therapeutics, Inc. (TNGX) is expected to report a quarterly loss of $0.34 per share, reflecting a year-over-year change of +2.9% [3] - Revenues are anticipated to be $6.27 million, which is a decrease of 3.1% from the same quarter last year [3] Earnings Expectations - Wall Street anticipates a year-over-year increase in earnings despite lower revenues, with the earnings report set to be released on May 12 [1][2] - The consensus EPS estimate has been revised 1.52% lower over the last 30 days, indicating a bearish sentiment among analysts [4][10] Earnings Surprise Prediction - The Most Accurate Estimate for Tango Therapeutics is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -2.19% [10][11] - The company currently holds a Zacks Rank of 4, which complicates the prediction of an earnings beat [11] Historical Performance - In the last reported quarter, Tango Therapeutics was expected to post a loss of $0.32 per share but actually reported a loss of $0.35, resulting in a surprise of -9.38% [12] - Over the past four quarters, the company has beaten consensus EPS estimates two times [13] Industry Comparison - Mirum Pharmaceuticals, Inc. (MIRM), another player in the Zacks Medical - Biomedical and Genetics industry, is expected to post a loss of $0.39 per share, indicating a year-over-year change of +27.8% [17] - Mirum's revenues are projected to be $98.47 million, up 42.3% from the previous year [17] - Despite a recent EPS estimate revision of 2.8% downwards, Mirum has a Zacks Rank of 2 (Buy) but an Earnings ESP of -4.27% [18]

Core Viewpoint - Tango Therapeutics, Inc. is set to report its first quarter 2025 financial results on May 12, 2025, before the U.S. financial markets open, and will not hold a conference call following the announcement [1]. Company Overview - Tango Therapeutics is a clinical-stage biotechnology company focused on discovering novel drug targets and advancing precision medicine for cancer treatment [2]. - The company employs the genetic principle of synthetic lethality to identify and develop therapies targeting critical cancer-related objectives [2].

Core Insights - Tango Therapeutics, Inc. announced that five abstracts have been accepted for poster presentations at the AACR Annual Meeting 2025, highlighting the company's commitment to advancing precision cancer medicines [1][2] Abstracts Accepted for Presentation - The first abstract focuses on the preclinical evaluation of CNS drug penetration of a novel series of MTAP-selective PRMT5 inhibitors, including TNG456, scheduled for presentation on April 27, 2025 [3] - The second abstract discusses TNG456 as a next-generation, brain-penetrant, MTA-cooperative PRMT5 inhibitor for treating solid tumors with MTAP loss, also set for April 27, 2025 [3] - The third abstract presents TNG462, an MTA-cooperative PRMT5 inhibitor, demonstrating strong efficacy in combination with targeted therapies in MTAP-null preclinical models, scheduled for April 28, 2025 [4] - The fourth abstract evaluates the impact of homozygous MTAP truncations on the clinical activity of MTA-cooperative PRMT5 inhibitors, to be presented on April 29, 2025 [4] - The fifth abstract covers the genetic and pharmacological disruption of the HBS1L/PELO complex, leading to tumor regressions in FOCAD-deleted cancers, also scheduled for April 29, 2025 [5] Company Overview - Tango Therapeutics is a clinical-stage biotechnology company focused on discovering novel drug targets and delivering precision medicine for cancer treatment, utilizing the genetic principle of synthetic lethality [5]